Omeros' narsoplimab pivotal trial data shared in oral presentation at 2021 annual congress of the european hematology association

Seattle--(business wire)--omeros corporation (nasdaq: omer) today announced that data on organ function improvement from its pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) were shared during an oral presentation at the virtual edition of the 26th congress of the european hematology association (eha). the presentation, entitled narsoplimab (oms721) treatment contributes to improvements in organ function in adu
OMER Ratings Summary
OMER Quant Ranking